Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with camrelizumab and apatinib for intermediate to advanced hepatocellular carcinoma
ChiCTR2100043828Phase 4Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, Rivoceranib and epirubicin in hepatocellular carcinoma (HCC) and liver cancer (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: objective response rate, progression-free survival and 3 more. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibepirubicin
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2100043828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043828.